Intravenous ketamine appears to be more efficacious than intranasal esketamine for the treatment of depression.
Comparative Efficacy of Racemic Ketamine and Esketamine for Depression Read More »
Hamilton Morris spent 3 days with Dr. Raquel Bennett (founder of KRIYA Institute) talking about therapeutic ketamine. Filmed in Hillsborough, CA in July 2017.
Hamilton’s Pharmacopeia – Ketamine – Season 2 Episode 5 Read More »
Clayton Culp, Hee Kee Kim and Salahadin Abdi Published 2 February 2021 | https://doi.org/10.3389/fphar.2020.599721 Abstract Ketamine, an N-methyl-D-aspartate receptor antagonist, is widely known as a dissociative anesthetic and phencyclidine derivative. Due to an undesirable adverse event profile when used as an anesthetic it had widely fallen out of human use in favor of more modern
Ketamine Use for Cancer and Chronic Pain Management Read More »
In the meantime, practitioners of this new kind of mental healthcare can use ketamine as their psychedelic agent; and some studies, such as the one Grant participated in, are even government funded. The Ketamine for Reduction of Alcoholic Relapse (Kare) study is a novel attempt to ease the huge burden on the NHS caused by alcohol-related illnesses.
Repeated ketamine infusions reduce PTSD symptom severity Read More »
Sub-anaesthetic doses of ketamine, a noncompetitive N-methyl-d-aspartate receptor antagonist provide rapid and long-lasting antidepressant effects in these patients, but the molecular mechanism of these effects remains unclear.
Antidepressant Actions of Ketamine Engage Cell-Specific Translation via eIF4E Read More »
Hartej Gill, Barjot Gill, Nelson B. Rodrigues, Orly Lipsitz, Joshua Daniel Rosenblat, Sabine El-Halabi, Flora Nasri, Rodrigo B. Mansur, Yena Lee, Roger S. McIntyre Published 23 November 2020 | https://doi.org/10.1016/j.neubiorev.2020.11.020 Abstract Replicated evidence has documented cognitive deficits in populations with treatment-resistant depression (TRD). Approximately 40 % of patients with MDD present with impairment of one
Paulo R. Shiroma, MD; Paul Thuras, PhD; Joseph Wels, MD; Christopher Erbes, PhD; Shannon Kehle-Forbes, PhD; and Melissa Polusny, PhD Published 10 November 2020 | https://doi.org/10.4088/JCP.20l13406 Abstract Prolonged exposure (PE) is a gold-standard trauma-focused therapy; however, clinical trials of trauma-based therapies in the military and veteran populations showed that up to 50% of participants failed
In the meantime, practitioners of this new kind of mental healthcare can use ketamine as their psychedelic agent; and some studies, such as the one Grant participated in, are even government funded. The Ketamine for Reduction of Alcoholic Relapse (Kare) study is a novel attempt to ease the huge burden on the NHS caused by alcohol-related illnesses.
The Real Pros and Cons of Ketamine Infusions Read More »
Can LSD and psilocybin provide relief to people suffering from difficult-to-treat conditions such as depression and anxiety? Robin Carhart-Harris is a neuroscientist and head of the Imperial Centre for Psychedelic Research, which builds on over a decade of pioneering work psychedelic research, including a clinical trial that has kick-started global efforts to develop psilocybin therapy into a licensed treatment for depression.
Ketamine Explained, The Next Big Antidepressant | The War on Drugs Read More »
Camilla Crisanti, Paolo Enrico, Alessio Fiorentini, Giuseppe Delvecchio, Paolo Brambilla Published 29 July 2020 | https://doi.org/10.1016/j.jad.2020.07.119 Abstract Background Most recent evidence support a rapid and sustained antidepressant effect of subanesthetic dose of intravenous ketamine in patients with major depressive disorder (MDD). However, clinical and animal studies investigating the effects of intravenous ketamine on specific functional